Disclosed Amino Acid Sequence Derived From Bacterium (e.g., Mycoplasma, Anaplasma, Etc.) Patents (Class 424/190.1)
-
Patent number: 8226958Abstract: A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.Type: GrantFiled: March 25, 2004Date of Patent: July 24, 2012Assignees: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Kowa Company, Ltd.Inventors: Toshihiro Nakashima, Takumi Sasaki, Kazuhiko Kimachi, Shigeki Kuwata, Tsukasa Nishihara, Atsuko Sakata, Masao Ohkuchi, Tomoyuki Koshi, Toshiyuki Edano
-
Patent number: 8226953Abstract: Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: GrantFiled: December 28, 2010Date of Patent: July 24, 2012Assignee: ID Biomedical Corporation of QuebecInventors: Bernard R. Brodeur, Clement Rioux, Martine Boyer, Isabelle Charlebois, Josée Hamel, Denis Martin
-
Publication number: 20120183570Abstract: Methods and compositions for reducing the incidence of C. jejuni bacteria infections in poultry and in humans and other animals are formulated to include C. jejuni antigens, and particularly CadF, FlpA and FlaA. The antigens may be provided in the form of polypeptides or by hosts that produce the antigens. Fibronectin binding proteins of C. jejuni may also be used to deliver substances of interest to humans and other animals.Type: ApplicationFiled: July 16, 2010Publication date: July 19, 2012Inventors: Michael Konkel, Tri Duong, Charlie Larson, Jason Neal-McKinney
-
Publication number: 20120177677Abstract: Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.Type: ApplicationFiled: July 15, 2010Publication date: July 12, 2012Applicant: VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon
-
Publication number: 20120177680Abstract: The present disclosure relates to proteins derived from OspC from bacteria of the genus Borrelia, in particular a protein which comprises a first OspC polypeptide, wherein the first OspC polypeptide is linked to a second OspC polypeptide via a disulphide bridge. The disclosure also relates to a method for the detection of antibodies against OspC and a method for the detection of a Borrelia infection, wherein a protein according to the disclosure is employed, and also to a diagnostic kit and a vaccine against Borrelia.Type: ApplicationFiled: March 22, 2012Publication date: July 12, 2012Applicant: EUROIMMUN Medizinische Labordiagnostika AGInventors: Lars Komorowski, Christian Probst, Anthonina Janssen, Winfried Stöcker
-
Publication number: 20120177679Abstract: Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.Type: ApplicationFiled: December 21, 2011Publication date: July 12, 2012Applicant: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPAInventors: LUIGI AURISICCHIO, DANIELA PERUZZI, NICOLA LA MONICA, GENNARO CILIBERTO, DOMENICO LAZZARO, FEDERICA MORI
-
Publication number: 20120177678Abstract: The present invention provides methods of treating, protecting against, and inducing an immune response against cervical dysplasia and cancer, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and an E7 and/or E6 antigen. The present invention also provides methods for inducing an anti-E7 CTL response in a human subject and treating HPV-mediated diseases, disorders, and symptoms, comprising administration of the recombinant Listeria strain.Type: ApplicationFiled: December 8, 2011Publication date: July 12, 2012Inventors: Yvonne PATERSON, John Rothman
-
Publication number: 20120171236Abstract: The published genomic sequence of Chlamydia pneumoniae reveals over 1000 putative encoded proteins but does not itself indicate which of these might be useful antigens for immunization and vaccination or for diagnosis. This difficulty is addressed by the invention, which provides a number of C. pneumoniae protein sequences suitable for vaccine production and development and/or for diagnostic purposes.Type: ApplicationFiled: January 9, 2012Publication date: July 5, 2012Applicant: NOVARTIS AGInventors: Giulio RATTI, Guido GRANDI
-
Publication number: 20120171214Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.Type: ApplicationFiled: March 14, 2012Publication date: July 5, 2012Applicant: ABSYNTH BIOLOGICS LIMITEDInventors: Simon J. FOSTER, Jorge GARCIA-LARA
-
Publication number: 20120171238Abstract: The invention discloses the use of a protein with an amino acid sequence according to SEQ. ID. NO. 1 or a naturally occurring fragment or variant thereof for identifying infections with S. aureus in a human sample. More specifically, IgE molecules specific for SEQ. ID. NO. 1 are detected in the sample of the patient. Many atopic dermatitis patients have IgE specific for SEQ. ID. NO. 1.Type: ApplicationFiled: September 10, 2010Publication date: July 5, 2012Applicant: BIOMAY AGInventors: Rudolf Valenta, Kavita Reginald, Kerstin Westritschnig, Birgit Linhart, Angelika Stöcklinger, Josef Thalhamer, Alexander M. Hirschi, Thomas Werfel, Elli Greisenegger, Tamara Kopp
-
Publication number: 20120171237Abstract: Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as Karp, Kato (Ktr56), Gilliam (Gmr56), and TA763 (TAr56). The invention is useful for detecting prior exposure to a number of strains of scrub typhus, based on the strength of reaction toward the chimeric protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects against heterologous infections.Type: ApplicationFiled: February 13, 2012Publication date: July 5, 2012Inventors: Wei-Mei Ching, Chien-Chung Chao
-
Patent number: 8211445Abstract: This disclosure concerns compositions and methods for the treatment and inhibition of infectious disease, particularly methicillin-resistant Staphylococcus. In certain embodiments, the disclosure concerns immunogenic peptides, for instance PSM peptides, which can be used to induce protective immunity against methicillin-resistant Staphylococcus. Also disclosed are methods of detecting methicillin-resistant staphylococcus in a sample, and methods of diagnosing methicillin-resistant staphylococcus in a subject.Type: GrantFiled: December 4, 2009Date of Patent: July 3, 2012Assignee: The United States of America, as represented by the Department of Health and Human ServicesInventors: Michael Otto, Rong Wang
-
Patent number: 8211437Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: GrantFiled: December 9, 2009Date of Patent: July 3, 2012Assignee: ID Biomedical Corporation of QuebecInventors: Josée Hamel, Bernard R. Brodeur, Isabelle Pineau, Denis Martin, Clement Rioux, Nathalie Charland
-
Publication number: 20120164166Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: ApplicationFiled: January 26, 2012Publication date: June 28, 2012Applicants: NOVARTIS AG, J. CRAIG VENTER INSTITUTE, INC.Inventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
-
Patent number: 8206724Abstract: The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a Chlamydia genome. In more specific aspects, the invention relates to methods of isolating such antigens and nucleic acids and to methods of using such isolated antigens for producing immune responses. The ability of an antigen to produce an immune response may be employed in vaccination or antibody preparation techniques.Type: GrantFiled: April 19, 2007Date of Patent: June 26, 2012Assignees: Auburn University, Board of Regents, The University of Texas SystemInventors: Stephen A. Johnston, Katherine Stemke-Hale, Kathryn F. Sykes, Bernhard Kaltenboeck
-
Patent number: 8206685Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.Type: GrantFiled: April 5, 2010Date of Patent: June 26, 2012Assignee: The Board of Trustees of The University of IllinoisInventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
-
Publication number: 20120156236Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: ApplicationFiled: January 26, 2012Publication date: June 21, 2012Applicants: NOVARTIS AG, J. CRAIG VENTER INSTITUTE, INC.Inventors: Claire FRASER, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
-
Publication number: 20120156211Abstract: Provided herein are compositions and methods for eliciting an immune response against Porphyromonas gingivalis. The compositions and methods relate to P. gingivalis polypeptides and fragments and variants thereof and the corresponding polynucleotides which are useful in the diagnosis, prevention and therapy of P. gingivalis infections (e.g. periodontitis). Antibodies against the polypeptides and compositions and methods including these antibodies are also disclosed. The disclosure also describes methods for the detection, prevention and treatment of P. gingivalis infection (e.g. periodontitis).Type: ApplicationFiled: July 30, 2010Publication date: June 21, 2012Inventors: Jacqueline Mccluskey, Robert Charlebois, Laurence Quemenuer, Jeremy Yethon, Michael Leach
-
Publication number: 20120148616Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: ApplicationFiled: January 26, 2012Publication date: June 14, 2012Applicants: NOVARTIS AG, J. CRAIG VENTER INSTITUTE, INC.Inventors: Claire FRASER, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
-
Publication number: 20120148614Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.Type: ApplicationFiled: December 8, 2011Publication date: June 14, 2012Inventors: Arne Forsgren, Kristian Riesbeck
-
Publication number: 20120148618Abstract: Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.Type: ApplicationFiled: February 6, 2012Publication date: June 14, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: MAURIZIO COMANDUCCI, MARIAGRAZIA PIZZA
-
Publication number: 20120148619Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.Type: ApplicationFiled: February 23, 2012Publication date: June 14, 2012Applicant: NOVARTIS AGInventors: Mario CONTORNI, Lorenzo Tarli
-
Publication number: 20120148615Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.Type: ApplicationFiled: January 24, 2012Publication date: June 14, 2012Inventors: Vega MASIGNANI, Beatrice Maria Arico
-
Publication number: 20120148617Abstract: Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.Type: ApplicationFiled: February 1, 2012Publication date: June 14, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Maurizio COMANDUCCI, Mariagrazia Pizza
-
Patent number: 8197826Abstract: The invention relates to an immunomodulatory product obtained from a Bifidobacterium culture, to the use thereof, especially as a medicament or a food ingredient, and to pharmaceutical or food compositions containing the same.Type: GrantFiled: April 8, 2004Date of Patent: June 12, 2012Assignee: Compagnie Gervais DanoneInventors: Valérie Petay, Francis Lecroix, Emmanuel Perrin, Charles Gontier, Jean-Pierre Blareau, Marie-Bénédicte Romond, Elisabeth Singer, Marie-Françoise Odou, Catherine Demailly-Mullie
-
Publication number: 20120141523Abstract: The present application relates to an immunogenic composition comprising a fragment of a staphylococcal Isd protein such as IsdA, IsdB, IsdC or IsdH which comprises a NEAT domain. Fusion proteins comprising a NEAT domain of a first staphylococcal Isd protein and a NEAT domain from a second Isd protein are also disclosed as well as fusion proteins comprising a NEAT domain of a staphylococcal Isd protein involved in an iron/heme uptake system and a ligand binding domain of a staphylococcal extracellular component binding protein, for example ClfA, ClfB, SdrC, SdrD or SdrE.Type: ApplicationFiled: August 3, 2010Publication date: June 7, 2012Inventors: Cindy Castado, Sophie Marie Jeanne Valentine Germain, Melanie Gilbert
-
Publication number: 20120141522Abstract: The present invention discloses amino acid sequences and nucleic acid sequences relating to a Streptococcus pneumoniae surface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa). The PPP exhibits the ability to reduce colonization of pneumococcal bacteria. Thus the present invention also pertains to compositions for the treatment and prophylaxis of infection or inflammation associated with bacterial infection.Type: ApplicationFiled: January 11, 2012Publication date: June 7, 2012Applicant: Wyeth LLCInventors: Bruce A. Green, Amy W. Masi
-
Publication number: 20120141521Abstract: The invention relates to immunogenic polypeptides derived from epitopes in a Streptococcus agalactiae (“GBS”) protein GBS 80 and their use as prophylactic, diagnostic and therapeutic compositions. The invention also provides nucleic acids encoding the immunogenic polypeptides. Also provided are vectors useful for making such immunogenic polypeptides and host cells transformed with such vectors. In particular, the invention relates to a group immunogenic polypeptides derived from GBS 80. The compositions may include one or more of the immunogenic polypeptides either alone or with other antigenic components. For example, the immunogenic polypeptides may be combined with other GBS antigens to provide therapeutic compositions with broader range.Type: ApplicationFiled: December 29, 2011Publication date: June 7, 2012Inventors: Domenico Maione, Guido Grandi, Nathalie Norais
-
Publication number: 20120141487Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a Moraxella catarrhalis (Meat) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Moraxella catarrhalis species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell which expresses such antigen. More specifically, such antigens are produced by or associated with bacterial infections caused by Moraxella catarrhalis.Type: ApplicationFiled: May 28, 2010Publication date: June 7, 2012Applicant: Intercell AGInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Julia Flor, Birgit Noiges, Wolfgang Schueler, Ulrike Schirmer, Verena Salletmayer, Mario Aistleithner, Stefan Seidel, Martin Oleksiewicz
-
Publication number: 20120135024Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: ApplicationFiled: March 23, 2011Publication date: May 31, 2012Applicants: NOVARTIS AG, J. CRAIG VENTER INSTITUTE, INC.Inventors: Claire FRASER, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
-
Publication number: 20120135027Abstract: Chimera proteins including: (i) at least one sequence of a DbpA protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii, and (ii) at least one sequence of an OspC protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii. Also, a method and a kit for the in vitro diagnosis of Lyme borreliosis using said proteins.Type: ApplicationFiled: August 26, 2010Publication date: May 31, 2012Applicant: BIOMERIEUXInventors: Lionel Levet, Odile Mejan-Letourneur
-
Publication number: 20120135026Abstract: Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N. meningitidis and N. gonorrhoeae.Type: ApplicationFiled: February 3, 2012Publication date: May 31, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Marzia Monica Giuliani, Mariagrazia Pizza, Rino Rappuoli
-
Publication number: 20120134999Abstract: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.Type: ApplicationFiled: September 7, 2011Publication date: May 31, 2012Inventors: Richard S. Stephens, Diane Kawa
-
Publication number: 20120135025Abstract: The present invention provides novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. The present invention further provides methods of using the antigens to elicit immune responses (e.g., T cell-mediated and/or B cell-mediated immune responses). The present invention provides methods of prophylaxis and/or treatment of chlamydia-mediated diseases comprising administering an immunogenic composition including one or more of the novel antigens described herein.Type: ApplicationFiled: October 20, 2011Publication date: May 31, 2012Applicant: GENOCEA BIOSCIENCES, INC.Inventors: Jessica Baker Flechtner, Kenya Prince Cohane, Todd Gierahn, Alexander Yao-Hsien Lee, George Rainer Siber
-
Patent number: 8187611Abstract: The present invention provides a purified peptide comprising at least one of the sequences LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a vaccine, a method to protect or treat an animal from anthrax toxin, a method of making a vaccine and the use of the peptide. The present invention also provides a monoclonal antibody that specifically binds to a peptide sequence comprising at least one of the following peptide sequences: LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a method to protect or treat an animal from anthrax toxin, a method of making a vaccine, a pharmaceutical composition, a method of making a pharmaceutical composition, and the use of the monoclonal antibody.Type: GrantFiled: October 5, 2010Date of Patent: May 29, 2012Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Nareen Abboud, Arturo Casadevall
-
Publication number: 20120128708Abstract: A method of diagnosing Mycobacterium tuberculosis infection in a human, or of determining whether a human has been exposed to Mycobacterium tuberculosis, comprising (i) contacting T-cells from said human with one or more of (a) a peptide having the sequence shown in SEQ ID NO 20, (b) a peptide having or comprising the sequence of at least 8 consecutive amino acids of the sequence shown in SEQ. ID NO 20; or (c) a peptide having or comprising a sequence which is capable of binding to a T-cell receptor which recognises a peptide as defined in (a) or (b); and (ii) determining whether any of the said T-cells recognise said peptide, wherein steps (i) and (ii) are optionally carried out in vitro. The peptide is the product of the RV3615c gene.Type: ApplicationFiled: April 9, 2010Publication date: May 24, 2012Inventor: Ajit Lalvani
-
Publication number: 20120128707Abstract: The invention provides proteins and nucleic acid sequences from Streptococcus Pneumoniae, together with a genome sequence. These are useful for the development of vaccines, diagnostics, and antibiotics.Type: ApplicationFiled: October 5, 2010Publication date: May 24, 2012Applicants: J. CRAIG VENTER INSTITUTE, NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: VEGA MASIGNANI, HERV¿ TETTELIN, CLAIRE FRASER
-
Publication number: 20120128709Abstract: The invention provides auto-inducible systems for expressing recombinant proteins of interest which take advantage of elements of quorum sensing (QS) systems of certain bacteria. These systems can be used to produce commercial quantities of proteins such as antigens, which can be used to prepare pharmaceutical compositions.Type: ApplicationFiled: May 28, 2010Publication date: May 24, 2012Inventors: Erwin Swennen, Salvatore Nocadello
-
Publication number: 20120121637Abstract: Chimeric fHbps that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.Type: ApplicationFiled: April 29, 2010Publication date: May 17, 2012Inventors: Dan M. Granoff, Peter Beernink
-
Publication number: 20120121639Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: ApplicationFiled: January 26, 2012Publication date: May 17, 2012Inventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Publication number: 20120121638Abstract: A medicament for the treatment or the prevention of a bacterial infection is disclosed which contains a polypeptide having a contiguous sequence of at least six amino acids of SEQ ID NO:1. Said polypeptide can be used for the preparation of a vaccine against an Enterococcus infection.Type: ApplicationFiled: April 26, 2010Publication date: May 17, 2012Inventors: Johannes Huebner, Andrea Kropec-Huener, Irina Sava
-
Publication number: 20120114684Abstract: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.Type: ApplicationFiled: September 30, 2011Publication date: May 10, 2012Applicant: CORIXA CORPORATIONInventors: Ajay Bhatia, Yasir A.W. Skeiky, Peter Probst
-
Publication number: 20120114686Abstract: Disclosed are methods and compositions for treating or preventing a Staphylococcus bacterial infection using a non-toxigenic Protein A (SpA) variant.Type: ApplicationFiled: April 5, 2010Publication date: May 10, 2012Applicant: UNIVERSITY OF CHICAGOInventors: Olaf Schneewind, Alice Cheng, Dominique M. Missiakas, Hwan Keun Kim
-
Publication number: 20120114685Abstract: The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.Type: ApplicationFiled: March 4, 2010Publication date: May 10, 2012Inventors: Matthew Seavey, Yvonne Paterson, Paulo Maciag, Duane Sewell, Catherine Sewell
-
Publication number: 20120114687Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: ApplicationFiled: December 22, 2011Publication date: May 10, 2012Applicant: STATENS SERUM INSTITUTInventors: Claus Aagard, Carina Vingsbo-Lundberg, Peter Andersen
-
Patent number: 8173774Abstract: The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of Staphylococcus aureus (‘CHIPS’), the polypeptide comprising a variant of the amino acid sequence of SEQ ID NO:1. Preferably, the polypeptide is a CHIPS variant wherein one or more of the following amino acids is modified: N31, S32, G33, L34, P35, K40, D42, R46, Y48, K50, G52, T53, K54, N55, S56, A57, Q58, K61, E67, K69, L76, N77, P79, D83, L90, K92, K100, K101, S104, K105, S107, Y108, N111 and G112. In a preferred embodiment, the polypeptide is less immunogenic hi humans than the wildtype CHIPS protein. The invention further provides methods of making and using such variant CHIPS polypeptides.Type: GrantFiled: April 20, 2007Date of Patent: May 8, 2012Assignee: Alligator Bioscience ABInventors: Christina Furebring, Johannes A. G. Van Strijp, Petrus J. A. Haas, Anna Rosen, Karin Haraldsson, Erika Gustafsson, Lena Schultz, Cornelis P. M. Van Kessel
-
Publication number: 20120107340Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.Type: ApplicationFiled: April 14, 2010Publication date: May 3, 2012Applicant: NOVARTIS AGInventors: Fabio Bagnoli, Massimilliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
-
Publication number: 20120107322Abstract: Compositions for preventing and/or treating S. pyogenes infection which comprise one or more active agents. The active agents are SLO antigens, nucleic acid molecules encoding the SLO antigens, and/or antibodies which selectively bind to the SLO antigens.Type: ApplicationFiled: October 20, 2011Publication date: May 3, 2012Applicant: NOVARTIS AGInventors: Maria SCARSELLI, Giuliano BENSI, Guido GRANDI
-
Publication number: 20120107339Abstract: Chimeric fHBPs that can elicit antibodies that are bactericidal for different fHBP variant strains of N. meningitidis, and methods of use, are provided.Type: ApplicationFiled: March 9, 2009Publication date: May 3, 2012Inventors: Dan M. Granoff, Peter Beernink, Jo Anne Welsch
-
Publication number: 20120107341Abstract: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the prevention and/or treatment of tuberculosis are also disclosed.Type: ApplicationFiled: December 20, 2011Publication date: May 3, 2012Inventors: David Lewinsohn, Deborah Lewinsohn